Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis centre.

Elexacaftor/Tezacaftor/Ivacaftor: Monitoring Liver Health in Cystic Fibrosis Patients

Elexacaftor/tezacaftor/ivacaftor (E/T/I) therapy has shown significant improvements in the health of many individuals with cystic fibrosis. However, monitoring liver function is crucial due to potential liver toxicity. This study examines the long-term effects of E/T/I on liver tests in a large group of cystic fibrosis patients at a single center.

E/T/I's Impact on Liver Function: A Comprehensive Assessment

The study found that while E/T/I therapy has proven beneficial for cystic fibrosis patients, it is important to closely monitor liver function due to potential risks of elevated transaminases and hepatotoxicity. The research emphasizes the need for continued monitoring of liver health in these patients.

Cystic Fibrosis Management: A Balancing Act

This research provides valuable information for managing cystic fibrosis patients on E/T/I therapy. Close monitoring of liver function is essential to ensure optimal patient care and mitigate any potential complications.

Dr. Camel's Conclusion

Imagine E/T/I therapy as a refreshing oasis in the arid landscape of cystic fibrosis. While this therapy offers significant benefits, it's important to keep a watchful eye on liver health, like a camel guarding its water source. This study reminds us that vigilance is crucial in managing complex conditions like cystic fibrosis.